RecruitingNot Applicable

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Canada120 participantsStarted 2015-12

Plain-language summary

By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 18 years.
✓. Patient diagnosis must be categorized as either (I) OR (II) OR (III) OR (IV):
✓. Disease amenable to biopsy or surgery for tissue procurement
✓. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
✓. Willingness and ability of patient to provide signed voluntary informed consent.

Exclusion criteria

✕. Clinically significant hepatic, renal, cardiac or other organ dysfunction likely to limit participation in clinical trials.
✕. Known brain metastasis
✕. Any condition that could interfere with a patient's ability to provide informed consent such as dementia or severe cognitive impairment.
✕. Any contraindication to undergoing a biopsy procedure.

What they're measuring

Measure of drug sensitive pPDX to a panel of drugs as a predictor of clinical response in matched host

Timeframe: up to 5 years

Rate of results reporting

Timeframe: up to 5 years

Rate of pPDX engraftment

Timeframe: up to 2 years

Trial details

NCT IDNCT02732860

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-01-04

Contact for this trial

David Cescon, MD

416-946-2245 Dave.Cescon@uhn.ca

View on ClinicalTrials.gov More Colorectal Neoplasms trials